Let’s talk about the newer medications that are making an impact.
Endometriosis, as you are aware, is a chronic and often debilitating condition that affects approximately one in nine women of reproductive age. Characterised by the growth of endometrial tissue (the inner lining of the uterus) outside the uterus, this condition can cause severe pain, infertility, and a significant impact on quality of life. Fortunately, advancements in hormonal therapies are providing new hope for those living with endometriosis.
Ryeqo: A Newly Approved Treatment for Moderate to Severe Endometriosis Pain
One of the most exciting developments in endometriosis treatment is the approval of Ryeqo, a medication specifically designed to improve moderate to severe endometriosis pain. Ryeqo is a combination therapy that includes relugolix (a GnRH receptor antagonist), estradiol (an estrogen), and norethisterone acetate (a progestin).
This innovative treatment suppresses estrogen production, reduces the hormonal stimulation of endometriosis tissue, and maintains bone density by adding low-dose estrogen and progestin.
Ryeqo was previously indicated for the treatment of moderate symptoms of uterine fibroids in women of reproductive age. Recent clinical trials have also demonstrated that Ryeqo is effective in women with endometriosis, and it has the potential to significantly reduce menstrual and non-menstrual pelvic pain, improving daily function and quality of life.
However, it’s not for everyone. Ryeqo is not recommended if you have allergies, blood clots, clotting disorders, osteoporosis, certain breast or ovarian cancers, liver disease, pregnancy, unexplained bleeding, or use hormonal contraceptives. Avoid if you experience migraines with neurological symptoms.
For many women who have struggled with traditional hormonal treatments, Ryeqo offers a compelling alternative with a well-tolerated side effect profile. Its approval marks a significant step in providing more targeted, non-surgical options for managing endometriosis symptoms.
Dienogest (Visanne) Now Listed on the PBS
Another significant development is that women in Australia now have improved access to effective endometriosis treatment. Dienogest (Visanne) has been listed on the Pharmaceutical Benefits Scheme (PBS) for the first time, making it a more affordable option for endometriosis management.
Dienogest is a progestin that works by suppressing the growth of endometriosis tissue. Unlike traditional oral contraceptives, which are commonly prescribed for treating endometriosis, Dienogest is specifically formulated to treat endometriosis and has been shown to significantly reduce pelvic pain, inflammation, and lesion size over time.
Dienogest is NOT a contraceptive.
The PBS listing of Dienogest is an important milestone, ensuring that more women can access this effective therapy without the financial burden. Given that endometriosis is a lifelong condition requiring long-term management, the affordability of treatments like Dienogest is crucial for improving patient outcomes.
The Future of Endometriosis Treatment – These recent advancements highlight a growing recognition of the need for more effective and accessible treatments for endometriosis. While hormonal therapies like Ryeqo and Dienogest provide substantial symptom relief, research continues into new treatments, including non-hormonal therapies, surgical innovations, and potential future cures.
For women living with endometriosis, these new treatment options represent not only medical progress but also a validation of their experiences and struggles. With increased awareness and continued investment in research, there is hope that the future will bring even more breakthroughs in managing and eventually eradicating this challenging condition.
At AEVAFEM, our specialists will take the time required to make you feel comfortable, alleviate the uncertainty of having a gynaecological procedure or surgery and help you make an informed decision on the best treatment solution for you.
Dr Yogesh Nikam is a Specialist Gynaecologist, with a special interest in complex gynaecological issues. He leads a multi-disciplinary team involving Colorectal surgeons, Urologists, Pain specialists and Allied health specialists in treating endometriosis.
Call 1300 724 380 to make an appointment.
Disclaimer: The information provided does not constitute medical, professional or expert advice. Readers should seek professional medical assistance if they suffer from any medical problem. I have written this blog in good faith, based on the best available current evidence; however, I cannot promise and assume no legal liability or responsibility for the currency or completeness of the information. References can be provided on request.